Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily in patients with chronic stable angina pectoris

Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily in patients with chronic stable angina pectoris: a multicentre randomised double blind study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN84362208

Enrollment

150

Registered

2012-04-04

Start date

2012-03-12

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina pectoris attacks Circulatory System Angina pectoris

Interventions

A randomised, double-blind, parallel-group study in patients treated for 12 weeks - Two arms: trimetazidine MR 80mg once daily or trimetazidine MR 35mg twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female patient 2. More than or equal to 21 years old 3. Any ethnic origin 4. Patients with a prior diagnosis of stable angina pectoris of effort

Exclusion criteria

Exclusion criteria: 1. History of acute coronary syndrome within previous 3 months 2. Coronary revascularisation procedure within previous 3 months 3. Canadian Cardiovascular Society (CCS) class 4 angina pectoris

Design outcomes

Primary

Measure	Time frame
1. Emergent adverse events 2. Blood pressure 3. Weight 4. Laboratory examinations: biochemical and haematological parameters 5.12-lead electrocardiogram 6. CCS classification of symptoms of angina pectoris	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Russian Federation, Serbia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026